Last edition
News about "Claudin-1 targeted cancer therapy"
Alentis and PinotBio Partner to Develop Claudin-1 ADCs
Alentis and PinotBio have partnered to develop next-generation claudin-1 ADCs, with Alentis securing an exclusive option to license novel linkers and payloads.
Claudin-1 Targeted Cancer Therapy | 14/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members